Intelligent Bio Solutions (INBS) Stock: Buy, Sell, or Hold?
INBS - Intelligent Bio Solutions Inc. Common Stock
$2.13
-0.06 (-2.74%)
▼
5d:
-7.39%
30d:
-16.14%
90d:
-11.06%
HOLD
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 21, 2026
0d
Get Alerted When INBS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INBS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: INBS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: INBS is currently trading at $2.13, which is considered slightly low relative to its 30-day fair value range of $2.03 to $2.77. From a valuation perspective, the stock is trading at a discount (Forward PE: -0.4) compared to its historical average (13.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, INBS is in a downtrend. Immediate support is located at $2.05, while resistance sits at $2.84.
Market Sentiment: INBS scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $12.00 (+463.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INBS is in a downtrend. Immediate support is located at $2.05, while resistance sits at $2.84.
Market Sentiment: INBS scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $12.00 (+463.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.03 -
$2.77
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (76/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 463.4% below Wall St target ($12.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 26% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-7.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$2.03 -
$2.77
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.05
Resistance Level
$2.84
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.41
Wall Street Target
$12.00
(+463.4%)
Revenue Growth (YoY)
35.8%
Profit Margin
-294.9%
PE vs Historical
-0.4 vs 13.0
CHEAP
Share & Embed Analysis
Last updated: September 13, 2026 11:26 AM ET
Data refreshes hourly during market hours. Next update: 12:26 PM
Data refreshes hourly during market hours. Next update: 12:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INBS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$62 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$376 | 44 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 41 HOLD |